Merck to buy cancer drug developer in deal that could be worth more than $2B By: Philadelphia Business Journal via Business Journals May 21, 2019 at 09:00 AM EDT Merck's deal for Dallas-based Peloton Therapeutics includes an upfront payment of $1.05 billion. Read More >>